BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26658808)

  • 1. Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism.
    Ozolins A; Narbuts Z; Vanags A; Simtniece Z; Visnevska Z; Akca A; Wirowski D; Gardovskis J; Strumfa I; Goretzki PE
    Langenbecks Arch Surg; 2016 Nov; 401(7):943-951. PubMed ID: 26658808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
    Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
    Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
    Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
    Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
    Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
    Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
    Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
    Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
    Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining a molecular phenotype for benign and malignant parathyroid tumors.
    Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
    Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
    Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
    J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of parafibromin expression in a subset of parathyroid adenomas.
    Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
    Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
    Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
    Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Characteristics of Large Parathyroid Adenomas.
    Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
    World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
    Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
    PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
    Juhlin CC; Nilsson IL; Johansson K; Haglund F; Villablanca A; Höög A; Larsson C
    Endocr Pathol; 2010 Sep; 21(3):166-77. PubMed ID: 20473645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
    Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
    Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.
    Woodard GE; Lin L; Zhang JH; Agarwal SK; Marx SJ; Simonds WF
    Oncogene; 2005 Feb; 24(7):1272-6. PubMed ID: 15580289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into Hyperparathyroidism-Jaw Tumour Syndrome: From Endocrine Acumen to the Spectrum of
    Gheorghe AM; Sima OC; Florescu AF; Ciuche A; Nistor C; Sandru F; Carsote M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation.
    Cetani F; Pardi E; Ambrogini E; Viacava P; Borsari S; Lemmi M; Cianferotti L; Miccoli P; Pinchera A; Arnold A; Marcocci C
    Endocr Relat Cancer; 2007 Jun; 14(2):493-9. PubMed ID: 17639062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
    Juhlin CC; Nilsson IL; Lagerstedt-Robinson K; Stenman A; Bränström R; Tham E; Höög A
    Mod Pathol; 2019 Jul; 32(8):1082-1094. PubMed ID: 30923346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern experience with aggressive parathyroid tumors in a high-volume New England referral center.
    Quinn CE; Healy J; Lebastchi AH; Brown TC; Stein JE; Prasad ML; Callender GG; Carling T; Udelsman R
    J Am Coll Surg; 2015 Jun; 220(6):1054-62. PubMed ID: 25488353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.